Compare TPB & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPB | TWST |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2016 | 2018 |
| Metric | TPB | TWST |
|---|---|---|
| Price | $104.62 | $31.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $93.75 | $46.33 |
| AVG Volume (30 Days) | 252.0K | ★ 1.8M |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | ★ 0.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $435,716,000.00 | $376,572,000.00 |
| Revenue This Year | $29.47 | $15.19 |
| Revenue Next Year | $10.28 | $15.10 |
| P/E Ratio | $529.09 | ★ N/A |
| Revenue Growth | ★ 51.72 | 20.32 |
| 52 Week Low | $51.48 | $23.30 |
| 52 Week High | $110.55 | $55.33 |
| Indicator | TPB | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 66.74 | 51.15 |
| Support Level | $96.15 | $31.19 |
| Resistance Level | $106.75 | $33.31 |
| Average True Range (ATR) | 2.83 | 1.65 |
| MACD | 0.39 | 0.21 |
| Stochastic Oscillator | 84.23 | 55.56 |
Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.